Published in Gastroenterology on December 01, 1999
Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev (2002) 2.29
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer (2004) 1.43
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut (2002) 1.17
Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut (2008) 1.12
New life in a sleeper: thalidomide and Crohn's disease. Gastroenterology (1999) 1.10
Thalidomide for treatment of severe intestinal bleeding. Gut (2004) 1.09
Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut (2002) 1.00
Thalidomide for Crohn's disease. Gastroenterology (2000) 0.98
Curcumin suppresses invasiveness and vasculogenic mimicry of squamous cell carcinoma of the larynx through the inhibition of JAK-2/STAT-3 signaling pathway. Am J Cancer Res (2014) 0.88
Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J (2003) 0.86
Thalidomide induces mucosal healing in Crohn's disease: case report. World J Gastroenterol (2011) 0.86
Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production. World J Gastroenterol (2007) 0.86
Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat - role of endothelial cell-leukocyte interaction. Br J Pharmacol (2001) 0.84
Management of inflammatory bowel disease. Postgrad Med J (2004) 0.83
Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis. Int J Colorectal Dis (2004) 0.83
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Ther Adv Hematol (2011) 0.82
Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease. Expert Opin Drug Saf (2012) 0.79
Effect of cyclosporine in a murine model of experimental colitis. Dig Dis Sci (2002) 0.77
Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues. J Clin Immunol (2001) 0.77
Newer Therapies for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2004) 0.77
Infliximab treatment for Crohn's disease. Postgrad Med J (2001) 0.77
Crohn's disease: evidence for involvement of unregulated transcytosis in disease etio-pathogenesis. World J Gastroenterol (2011) 0.76
Effective treatment of gastrointestinal bleeding with thalidomide - Chances and limitations. World J Gastroenterol (2016) 0.75
Intractable insomnia after cessation of treatment with thalidomide. Gastroenterology (2001) 0.75
Thalidomide for inflammatory bowel disease: Systematic review. Medicine (Baltimore) (2016) 0.75
Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Exp Mol Med (2017) 0.75
Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients. Medicine (Baltimore) (2017) 0.75
Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. Therap Adv Gastroenterol (2017) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science (2001) 22.06
HMG-1 as a late mediator of endotoxin lethality in mice. Science (1999) 17.72
Health information on the Internet: accessibility, quality, and readability in English and Spanish. JAMA (2001) 15.23
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature (2000) 11.49
High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med (2000) 7.38
Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell (1999) 6.59
Regulation of flowering time by Arabidopsis photoreceptors. Science (1998) 5.11
VPS27 controls vacuolar and endocytic traffic through a prevacuolar compartment in Saccharomyces cerevisiae. J Cell Biol (1995) 5.04
Neuraxial block, death and serious cardiovascular morbidity in the POISE trial. Br J Anaesth (2013) 4.60
Activation of EGFP expression by Cre-mediated excision in a new ROSA26 reporter mouse strain. Blood (2001) 3.93
Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology (2000) 3.90
Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell (1998) 3.86
Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc Natl Acad Sci U S A (1999) 3.79
Rhabdomyolysis. Intern Emerg Med (2007) 3.56
Enhancement of blue-light sensitivity of Arabidopsis seedlings by a blue light receptor cryptochrome 2. Proc Natl Acad Sci U S A (1998) 3.34
Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology (1996) 3.08
A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A (1996) 3.07
Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J Immunol (1997) 3.05
Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J Biol Chem (1993) 3.02
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 2.99
Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med (2004) 2.94
Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med (2000) 2.93
Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology (1991) 2.93
Does oxidative damage to DNA increase with age? Proc Natl Acad Sci U S A (2001) 2.91
Fungi isolated from tobacco leaves and brown-spot lesions before and after flue-curing. Appl Microbiol (1968) 2.87
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80
HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med (2001) 2.80
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet (2001) 2.79
Antagonistic actions of Arabidopsis cryptochromes and phytochrome B in the regulation of floral induction. Development (1999) 2.76
Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut (2000) 2.71
Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. J Biol Chem (2001) 2.57
Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation (2000) 2.56
A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci U S A (1997) 2.55
Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut (2000) 2.47
High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum (2002) 2.45
Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology (2012) 2.45
The product of the pleiotropic Escherichia coli gene csrA modulates glycogen biosynthesis via effects on mRNA stability. J Bacteriol (1995) 2.40
Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology (1998) 2.38
Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer (1998) 2.36
Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol (2001) 2.36
Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut (1993) 2.35
Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant (2006) 2.29
Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell (2001) 2.29
A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol (1997) 2.28
Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum (2003) 2.26
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia (2009) 2.25
Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol (2000) 2.22
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther (2010) 2.20
Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat (2008) 2.19
CD8(+) T-cell selection, function, and death in the primary immune response in vivo. J Clin Invest (2000) 2.19
Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol (2001) 2.14
Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology (1998) 2.12
Inhibition of nuclear hormone receptor activity by calreticulin. Nature (1994) 2.11
Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology (2000) 2.10
Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology (1993) 2.10
Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry (1999) 2.10
Pleiotropic regulation of central carbohydrate metabolism in Escherichia coli via the gene csrA. J Biol Chem (1995) 2.10
Long-term outcomes of thalidomide in refractory Crohn's disease. Aliment Pharmacol Ther (2014) 2.06
Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1991) 2.06
Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci (2000) 2.06
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med (1991) 2.03
The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol (2000) 2.03
Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res (2000) 2.02
High mobility group 1 B-box mediates activation of human endothelium. J Intern Med (2003) 2.00
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol (1999) 1.93
E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis. Mol Cell Biol (2001) 1.91
Electrical properties and conduction in reperfused papillary muscle. Circ Res (2001) 1.91
Rap1 GTPase-activating protein SPA-1 negatively regulates cell adhesion. J Biol Chem (1999) 1.86
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 1.84
Induction of alloreactive cytotoxic T cells by acute virus infection of mice. J Immunol (1986) 1.84
Molecular mechanisms of BK channel activation. Cell Mol Life Sci (2009) 1.81
Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol (1999) 1.80
Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ (2008) 1.80
Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol (2000) 1.77
An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis (2001) 1.77
A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab (1999) 1.75
Communicating about risk of infectious diseases. JAMA (1996) 1.74
Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology (1995) 1.74
A genome-wide search identifies potential new susceptibility loci for Crohn's disease. Inflamm Bowel Dis (1999) 1.74
Mutations affecting the development of the embryonic zebrafish brain. Development (1996) 1.73
Knockout mice heterozygous for Sod2 show alterations in cardiac mitochondrial function and apoptosis. Am J Physiol Heart Circ Physiol (2001) 1.71
Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost (2005) 1.70
Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J Immunol (1995) 1.70
Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology (1992) 1.67
Genetic dissection of ethanol tolerance in the budding yeast Saccharomyces cerevisiae. Genetics (2006) 1.67
Orientation of prophage Mu. Virology (1973) 1.67
Molecular genetic analysis of Rts1p, a B' regulatory subunit of Saccharomyces cerevisiae protein phosphatase 2A. Mol Cell Biol (1997) 1.66